Table 5.

High on-treatment residual platelet reactivity (HRPR) by light transmission aggregometry (LTA), the VerifyNow P2Y12 assay, multiple electrode platelet aggregometry (MEA), and the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay in clopidogrel-treated patients (n=301) without and with hyperuricemia. Measurements by LTA, the VerifyNow P2Y12 assay, MEA, and the VASP assay were available for 299, 300, 293, and 299 patients, respectively

	No hyperuricemia (n = 218)	Hyperuricemia (n = 83)	p
HRPR LTA	8.8%	18.3%	0.02
HRPR VerifyNow P2Y12 assay	39.6%	59%	0.003
HRPR MEA	33.6%	46.3%	0.04
HRPR VASP assay	41.2%	57.8%	0.01